Ergomed Stock Price, News & Analysis (LON:ERGO)

GBX 189.25 5.25 (2.85 %)
(As of 12/12/2017 11:07 AM ET)
Previous CloseGBX 184
Today's RangeGBX 189.25 - GBX 190
52-Week RangeGBX 143.21 - GBX 225
Volume1,794 shs
Average Volume24,154 shs
Market Capitalization£68.81 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Ergomed (LON:ERGO)

Ergomed logoErgomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research services (CRS), and drug safety and medical information services (DS&MI). It provides a range of clinical trial planning, management and monitoring services. It is focused on oncology, neurology and immunology, and the development of orphan drugs. It has two businesses: Services Business and Co-Development Business. The Services Business is a clinical research business providing services to the pharmaceutical and biotechnology industry. The Co-Development Business is a portfolio of partnerships with pharmaceutical and biotechnology companies, providing its drug development services in exchange for a carried interest in any revenues attributable to the drug asset, including out licensing milestones, as well as sales of the product. It provides clinical development, trial management and pharmacovigilance services to over 100 clients.

Receive ERGO News and Ratings via Email

Sign-up to receive the latest news and ratings for ERGO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolLON:ERGO
CUSIPN/A
Phone+44-1483-503205

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSGBX 0.01
Net IncomeN/A
Net Margins2.07%
Return on Equity2.69%
Return on Assets1.73%

Miscellaneous

EmployeesN/A
Outstanding Shares42,680,000

Ergomed (LON:ERGO) Frequently Asked Questions

What is Ergomed's stock symbol?

Ergomed trades on the London Stock Exchange (LON) under the ticker symbol "ERGO."

How were Ergomed's earnings last quarter?

Ergomed PLC (LON:ERGO) posted its earnings results on Monday, September, 18th. The company reported $1.20 EPS for the quarter. The firm had revenue of $22.91 million for the quarter. Ergomed had a return on equity of 2.69% and a net margin of 2.07%. View Ergomed's Earnings History.

Where is Ergomed's stock going? Where will Ergomed's stock price be in 2017?

3 brokers have issued 12-month target prices for Ergomed's shares. Their predictions range from GBX 300 to GBX 360. On average, they anticipate Ergomed's share price to reach GBX 321.33 in the next twelve months. View Analyst Ratings for Ergomed.

Who are some of Ergomed's key competitors?

Who are Ergomed's key executives?

Ergomed's management team includes the folowing people:

  • Dan Weng, Chief Executive Officer, Director
  • Miroslav Reljanovic, Executive Vice Chairman of the Board
  • Stephen A. Stamp, Chief Financial Officer, Director (Age 54)
  • Jan Petracek, Chief Executive Officer of PrimeVigilance
  • Andrew Mackie, Chief Business Officer, Executive Director (Age 50)
  • Danko Dominis, Ergomed Head of Business Development
  • Branka Duvnjak, Ergomed Head of Site Management
  • Terry L. Murdock, President of North America, Executive Director of Global Clinical Operations (Age 49)
  • Chris Wilson, Head of Quality and Regulatory
  • Peter Lutz George, Non-Executive Chairman of the Board

How do I buy Ergomed stock?

Shares of Ergomed and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Ergomed's stock price today?

One share of Ergomed stock can currently be purchased for approximately GBX 189.25.

How big of a company is Ergomed?

Ergomed has a market capitalization of £68.81 million.

How can I contact Ergomed?

Ergomed's mailing address is 26-24 Frederick Sanger Road, GUILDFORD, GU2 7YD, United Kingdom. The company can be reached via phone at +44-1483-503205.


MarketBeat Community Rating for Ergomed (ERGO)

Community Ranking:  3.9 out of 5 (star star star)
Outperform Votes:  156 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  202
MarketBeat's community ratings are surveys of what our community members think about Ergomed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ergomed (LON:ERGO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 321.33GBX 321.33GBX 313GBX 313

Ergomed (LON:ERGO) Consensus Price Target History

Price Target History for Ergomed (LON:ERGO)

Ergomed (LON:ERGO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
10/23/2017Numis SecuritiesBoost Price TargetBuyGBX 280 -> GBX 300View Rating Details
5/2/2017Stifel NicolausLower Price TargetBuyGBX 315 -> GBX 304View Rating Details
4/21/2017N+1 SingerBoost Price TargetBuyGBX 293 -> GBX 360View Rating Details
(Data available from 12/12/2015 forward)

Earnings

Ergomed (LON:ERGO) Earnings History and Estimates Chart

Earnings by Quarter for Ergomed (LON:ERGO)

Ergomed (LON ERGO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/18/2017S1 2017GBX 1.20GBX 2,291 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Ergomed (LON:ERGO) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Ergomed (LON:ERGO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Ergomed (LON ERGO) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Ergomed (LON:ERGO)

Ergomed (LON ERGO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/3/2017Peter GeorgeInsiderBuy100,000GBX 190£190,000
7/20/2015Reljanovic,MiroslavInsiderSell3,958,020GBX 170£6,728,634
(Data available from 1/1/2013 forward)

Headlines

Ergomed (LON ERGO) News Headlines

Source:
DateHeadline
Allergy Therapeutics And Ergomed Ink Co-Development CollaborationAllergy Therapeutics And Ergomed Ink Co-Development Collaboration
www.morningstar.co.uk - December 12 at 9:45 AM
Ergomed Plc breached its 50 day moving average in a Bearish Manner : ERGO-GB : November 21, 2017Ergomed Plc breached its 50 day moving average in a Bearish Manner : ERGO-GB : November 21, 2017
finance.yahoo.com - November 21 at 5:12 AM
Have Investors Already Priced In Ergomed plc’s (AIM:ERGO) Growth?Have Investors Already Priced In Ergomed plc’s (AIM:ERGO) Growth?
finance.yahoo.com - November 17 at 12:23 PM
Ergomed PLC (ERGO) PT Raised to GBX 300 at Numis Securities LtdErgomed PLC (ERGO) PT Raised to GBX 300 at Numis Securities Ltd
www.americanbankingnews.com - October 23 at 6:08 AM
Ergomeds first-in-class haemostat, PeproStat(TM), reports positive top-line results and meets key endpoints in Phase II studyErgomed's first-in-class haemostat, PeproStat(TM), reports positive top-line results and meets key endpoints in Phase II study
globenewswire.com - October 23 at 3:27 AM
Ergomed Plc – Value Analysis (LONDON:ERGO) : October 12, 2017Ergomed Plc – Value Analysis (LONDON:ERGO) : October 12, 2017
finance.yahoo.com - October 12 at 7:10 PM
Ergomed Plc breached its 50 day moving average in a Bearish Manner : ERGO-GB : October 11, 2017Ergomed Plc breached its 50 day moving average in a Bearish Manner : ERGO-GB : October 11, 2017
finance.yahoo.com - October 11 at 7:54 PM
Numis Securities Ltd Reiterates "Buy" Rating for Ergomed PLC (ERGO)Numis Securities Ltd Reiterates "Buy" Rating for Ergomed PLC (ERGO)
www.americanbankingnews.com - October 7 at 6:44 PM
Ergomed Plc breached its 50 day moving average in a Bullish Manner : ERGO-GB : September 28, 2017Ergomed Plc breached its 50 day moving average in a Bullish Manner : ERGO-GB : September 28, 2017
finance.yahoo.com - October 2 at 2:57 PM
Ergomed Partners Boryung In South Korea Under First Haemostat DealErgomed Partners Boryung In South Korea Under First Haemostat Deal
www.morningstar.co.uk - September 27 at 6:31 PM
Ergomed PLC (ERGO) Receives Buy Rating from Numis Securities LtdErgomed PLC (ERGO) Receives Buy Rating from Numis Securities Ltd
www.americanbankingnews.com - September 24 at 4:38 PM
Ergomed Half Years Results "Solid" With Revenue Growth Of 31%Ergomed Half Years Results "Solid" With Revenue Growth Of 31%
www.morningstar.co.uk - September 19 at 4:14 AM
Ergomed PLC (ERGO) Announces  Earnings ResultsErgomed PLC (ERGO) Announces Earnings Results
www.americanbankingnews.com - September 18 at 7:18 AM
Ergomed Completes Recruitment For PeproStat Phase IIb Study - London South East (registration) (blog)Ergomed Completes Recruitment For PeproStat Phase IIb Study - London South East (registration) (blog)
www.lse.co.uk - July 25 at 5:32 AM
Ergomed Completes Recruitment For PeproStat Phase IIb StudyErgomed Completes Recruitment For PeproStat Phase IIb Study
www.morningstar.co.uk - July 25 at 12:31 AM
Investor Meeting - London South East (registration) (blog)Investor Meeting - London South East (registration) (blog)
www.lse.co.uk - July 6 at 7:38 PM
PeproStat study passes recruitment mid-point - London South East (registration) (blog)PeproStat study passes recruitment mid-point - London South East (registration) (blog)
www.lse.co.uk - June 21 at 6:34 PM
Ergomed Hires Weng As CEO As Founder Moves To Executive Vice ChairmanErgomed Hires Weng As CEO As Founder Moves To Executive Vice Chairman
www.morningstar.co.uk - June 16 at 3:39 PM
Ergomed Co-Development Partner Trial Fails To Meet Primary EndpointErgomed Co-Development Partner Trial Fails To Meet Primary Endpoint
www.morningstar.co.uk - May 3 at 9:15 AM
Brexit could cut U.K. access to new drugs: ErgomedBrexit could cut U.K. access to new drugs: Ergomed
www.marketwatch.com - March 29 at 11:32 AM
Ergomed Revenue Rises In 2016 As Contract Wins Surge - Finance ... - London South East (registration) (blog)Ergomed Revenue Rises In 2016 As Contract Wins Surge - Finance ... - London South East (registration) (blog)
www.lse.co.uk - January 17 at 5:44 PM
Ergomed Revenue Rises In 2016 As Contract Wins SurgeErgomed Revenue Rises In 2016 As Contract Wins Surge
www.morningstar.co.uk - January 17 at 5:34 AM
Ergomed welcomes expansion of Sickle Cell Disease studyErgomed welcomes expansion of Sickle Cell Disease study
www.msn.com - November 16 at 10:38 PM
Ergomed Signs Co-Development Deal With Swedens Asarina PharmaErgomed Signs Co-Development Deal With Sweden's Asarina Pharma
www.morningstar.co.uk - November 1 at 9:12 AM

SEC Filings

Ergomed (LON:ERGO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Ergomed (LON ERGO) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.